Herantis Awaits CDNF Results This Year In Parkinson's Disease
Hopes To Improve Investor Profile With Dual Stock Market Listing
Executive Summary
Executive Interview: Reducing “ER stress” is one of the potential mechanisms of action of a novel candidate Parkinson’s agent being evaluated by Finland’s Herantis, which completed an additional stock market listing, in Sweden, last month.